{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:46:47Z","timestamp":1794703607871,"version":"4.9.1"},"reference-count":182,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Analytical Chemistry"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/10408347.2025.2512443","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:17:24Z","timestamp":1749539844000},"page":"2275-2300","source":"Crossref","is-referenced-by-count":16,"title":["Innovations in the Detection of N-Nitrosamine Impurities in Pharmaceuticals: Analytical and Regulatory Challenges"],"prefix":"10.1080","volume":"56","author":[{"given":"Yunes M. M. A.","family":"Alsayadi","sequence":"first","affiliation":[{"name":"University Institute of Pharma Sciences, Chandigarh University","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Dogra","sequence":"additional","affiliation":[{"name":"Dipartimento di Chimica, Universit\u00e0 di Torino","place":["Torino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Arora","sequence":"additional","affiliation":[{"name":"University Institute of Pharma Sciences, Chandigarh University","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Shiven","sequence":"additional","affiliation":[{"name":"University Institute of Pharma Sciences, Chandigarh University","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sab.2023.106689"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.017"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcoa.2022.100037"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2023.12.009"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000323"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108864"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.12.022"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02120"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105459"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.20959\/wjpr202111-21490"},{"key":"e_1_3_5_12_1","unstructured":"US Food & Drug Administration (USFDA). Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan Iosartan and Irbesartan). 2019. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan. (accessed Mar. 12 2025)."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.124102"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00473-w"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2011.06.024"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.05.022"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2022.2042671"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2018.04.030"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00153"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008x(75)90255-0"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.10.001"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.est.3c07461"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.04.021"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2022.12.010"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12070"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1757-837X.2010.00049.x"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2006.09.003"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202100435"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00100"},{"key":"e_1_3_5_30_1","unstructured":"US Food & Drug Administration (USFDA). FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Products; Press Announcement; U.S. Department of Health and Human Services: Silver Spring MD May 28 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-alerts-patients-and-health-care-professionals-nitrosamine-impurity-findings-certain-metformin. (accessed March 12 2025)."},{"key":"e_1_3_5_31_1","unstructured":"European Medicines Agency (EMA). Nitrosamine Impurities in Specific Medicines; Pharmacovigilance Referral Procedure; European Medicines Agency: Amsterdam Netherlands March 3 2021. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/referral-procedures-human-medicines\/nitrosamine-impurities\/nitrosamine-impurities-specific-medicines. (accessed March 12 2025)."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.1c00369"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104749"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105505"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104977"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.11.013"},{"key":"e_1_3_5_37_1","unstructured":"Italian Medicines A. (AIFA). Nitrosamine Impurities in CHAMPIX (Varenicline) - Assessment Report; AIFA Reference: 2021.07.15; Italian Medicines Agency: Rome 2021. https:\/\/www.aifa.gov.it\/documents\/20142\/1313724\/2021.07.15_NII_CHAMPIX_EN.pdf. (accessed March 11 2025)."},{"key":"e_1_3_5_38_1","unstructured":"US Food and Drug Administration (USFDA). Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry; US Department of Health and Human Services: Silver Spring MD September 2021 (Revised September 2024). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/control-nitrosamine-impurities-human-drugs. (accessed March 11 2025)."},{"key":"e_1_3_5_39_1","unstructured":"US Food and Drug Administration (USFDA). Sandoz Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100\u2009mg Extended-Release Tablets Due to Presence of Nitrosamine Impurity; Safety Recall Notice; US Department of Health and Human Services: Silver Spring MD March 21 2022. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/sandoz-inc-issues-nationwide-recall-13-lots-orphenadrine-citrate-100-mg-extended-release-tablets-due. (accessed March 11 2025)."},{"key":"e_1_3_5_40_1","unstructured":"Health Canada. Pfizer Recalls Inderal (Propranolol Hydrochloride) Capsules Due to Nitrosamine Impurity; Recall Alert; Health Canada: Ottawa ON March 1 2022. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/pfizer-recalls-inderal-propranolol-hydrochloride-capsules-due-nitrosamine-impurity. (accessed March 11 2025)."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.3400"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100186"},{"key":"e_1_3_5_43_1","unstructured":"U.S. Pharmacopeia (USP). Nitrosamine Impurities in Medicines: What\u2019s the Risk? Quality Matters Blog. March 21 2021. https:\/\/qualitymatters.usp.org\/nitrosamine-impurities-medicines-whats-risk. (accessed March 12 2025)."},{"key":"e_1_3_5_44_1","unstructured":"Health Canada. Nitrosamine Impurities in Medications; Drug and Health Product Information; Health Canada: Ottawa January 1 2025. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/nitrosamine-impurities.html. (accessed March 12 2025)."},{"key":"e_1_3_5_45_1","unstructured":"Health Sciences Authority (HSA). Singapore. Nitrosamine Impurities in Medicines: List of Impacted Products; Therapeutic Products Regulation; Health Sciences Authority: Singapore October 23 2024. https:\/\/www.hsa.gov.sg\/therapeutic-products\/medicines-quality-and-compliance-monitoring\/nitrosamine-impurities-in-medicines\/list-of-impacted-medicines. (accessed March 12 2025)."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00199"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3GC03478J"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105763"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.4c00133"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.4c00476"},{"key":"e_1_3_5_51_1","unstructured":"US Food and Drug Administration (USFDA). Center for Drug Evaluation and Research (CDER). CDER Nitrosamine Impurity Acceptable Intake Limits; Guidance for Industry; U.S. Department of Health and Human Services: Silver Spring MD March 2 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-nitrosamine-impurity-acceptable-intake-limits. (accessed March 20 2025)."},{"key":"e_1_3_5_52_1","volume-title":"Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities; Guidance for Industry;","author":"US Food and Drug Administration (USFDA)","year":"2023","unstructured":"US Food and Drug Administration (USFDA). Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities; Guidance for Industry; US Department of Health and Human Services: Silver Spring, MD, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommended-acceptable-intake-limits-nitrosamine-drug-substance-related-impurities. (accessed Mar. 20, 2025)."},{"key":"e_1_3_5_53_1","unstructured":"World Health Organization (WHO). Information Note: Nitrosamine Impurities in Medicines; WHO Medical Alert; World Health Organization: Geneva Switzerland 2019. https:\/\/cdn.who.int\/media\/docs\/default-source\/essential-medicines\/medical-alert-2019\/informationnotenitrosamine-impurities-nov2019en.pdf. (accessed Mar. 20 2025)."},{"key":"e_1_3_5_54_1","unstructured":"European Medicines Agency (EMA). Nitrosamine Impurities in Human Medicines; Pharmacovigilance Referral Procedure; European Medicines Agency: Amsterdam Netherlands 2021. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/referral-procedures-human-medicines\/nitrosamine-impurities. (accessed Mar. 20 2025)."},{"key":"e_1_3_5_55_1","unstructured":"European Medicines Agency (EMA.). Nitrosamine Impurities in Human Medicinal Products; Pharmacovigilance Referral; EMA\/351053\/2019 Rev 16; European Medicines Agency: Amsterdam Netherlands February 22 2024. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/referral-procedures-human-medicines\/nitrosamine-impurities. (accessed Mar. 20 2025)."},{"key":"e_1_3_5_56_1","unstructured":"European Medicines Agency (EMA). Questions and Answers for Marketing Authorisation Holders\/Applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products; Scientific Opinion EMEA\/H\/A53(1490); Committee for Medicinal Products for Human Use (CHMP): Amsterdam Netherlands August 2 2020. https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf. (accessed March 20 2025)."},{"key":"e_1_3_5_57_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R2); ICH Harmonised Guideline; Step 4 Version February 16 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0.pdf. (accessed March 20 2025)."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.782536"},{"key":"e_1_3_5_59_1","unstructured":"U.S. Food and Drug Administration (USFDA). Center for Drug Evaluation and Research (CDER). Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities; Guidance for Industry; U.S. Department of Health and Human Services: Silver Spring MD September 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-nitrosamine-impurity-acceptable-intake-limits. (accessed March 22 2025)."},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.02.028"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.4c00234"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618823458"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b19-00006"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113460"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106026"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114561"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121740"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121923"},{"key":"e_1_3_5_69_1","unstructured":"Swissmedic. Limit Test for the Determination of Nitrosamines by GC-MS\/MS; Analytical Method No. 31_PV_171; Swiss Agency for Therapeutic Products: Bern Switzerland November 2019. https:\/\/www.swissmedic.ch. (accessed March 22 2025)."},{"key":"e_1_3_5_70_1","unstructured":"Health Sciences Authority (HSA) Singapore. Determination of N-Nitrosodimethylamine (NDMA) in Metformin Products by HRAM-GCMS; Method No. PHARM NDMA EX_GCVersion 002; Applied Sciences Group Pharmaceutical Laboratory: Singapore May 14 2020. https:\/\/sa.gov.sg\/docs\/default-source\/announcements\/safety-alerts\/determination-of-ndma-in-metformin-products-by-hram-gcms.pdf. accessed March 22 2025)."},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25225304"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9414"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1039\/D1AY01036K"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/19440049.2019.1571287"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2015.10.045"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012125"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113582"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2020.121659"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2015.08.015"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2015.08.014"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.24200\/amecj.v5.i03.190"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.3390\/separations4040036"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/chromatography2030293"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2020.1788375"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.03.016"},{"key":"e_1_3_5_86_1","unstructured":"Yang J.; Marzan T.; Kakarla R.; Ye W.; Sommers C.; Rodriguez J.; Keire D. LC-HRMS Based Analytical Platform to Determine Nitrosamines in Pharmaceuticals: Modern Analytical Techniques to Meet Regulatory Needs; Scientific Poster; US Food and Drug Administration Center for Drug Evaluation and Research: Silver Spring MD 2021. https:\/\/www.fda.gov\/media\/149015\/download. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_87_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Metformin Drug Substance and Drug Product; Laboratory Method FY20-058-DPA-S; U.S. Department of Health and Human Services: Silver Spring MD February 4 2020. https:\/\/www.fda.gov\/media\/149015\/download. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_88_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Varenicline Nitrosamine Drug Substance-Related Impurity (NDSRI) in Varenicline Drug Product and Drug Substance; Guidance Document; U.S. Department of Health and Human Services: Silver Spring MD 2021. https:\/\/www.fda.gov\/media\/XXXXXX\/download. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_89_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of MNP in Rifampin and CPNP in Rifapentine Drug Substance and Drug Product; Laboratory Method FY20-203-DPA-S; U.S. Department of Health and Human Services: Silver Spring MD September 2 2020. https:\/\/www.fda.gov\/media\/XXXXXX\/download (. accessed Mar. 23 2025)."},{"key":"e_1_3_5_90_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product; Laboratory Method FY19-177-DPA-S; U.S. Department of Health and Human Services: Silver Spring MD 2019.https:\/\/www.fda.gov\/media\/XXXXXX\/download (accessed Mar. 23 2025)."},{"key":"e_1_3_5_91_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of N-Nitroso-Propranolol in Propranolol Hydrochloride Oral Solution; Guidance Document; U.S. Department of Health and Human Services: Silver Spring MD 2021. https:\/\/www.fda.gov\/media\/XXXXXX\/download. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_92_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product; FDA: Silver Spring MD 2020. https:\/\/www.fda.gov\/media\/138509\/download (accessed Mar. 23 2025)."},{"key":"e_1_3_5_93_1","unstructured":"US Food and Drug Administration (USFDA). Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of N-Nitroso-Bumetanide in Bumetanide Drug Products and Drug Substance; FDA: Silver Spring MD 2021. https:\/\/www.fda.gov\/media\/XXXXXX\/download (accessed Mar. 23 2025)."},{"key":"e_1_3_5_94_1","unstructured":"US Food and Drug Administration. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs; FDA: Silver Spring MD 2019. https:\/\/www.fda.gov\/media\/XXXXXX\/download. (accessed Mar. 23 2025)."},{"key":"#cr-split#-e_1_3_5_95_1.1","unstructured":"U.S. Food and Drug Administration (USFDA). Combined Direct Injection N-Nitrosodimethylamine (NDMA) N-Nitrosodiethylamine (NDEA) N-Nitrosoethylisopropylamine (NEIPA) N-Nitrosodiisopropylamine (NDIPA) and N-Nitrosodibutylamine (NDBA) Impurity Assay by GC-MS\/MS 2019"},{"key":"#cr-split#-e_1_3_5_95_1.2","unstructured":"pp. 1-6. https:\/\/www.fda.gov\/media\/123409\/download?attachment. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_96_1","unstructured":"US Food and Drug Administration (USFDA). Combined Headspace N-Nitrosodimethylamine (NDMA) N-Nitrosodiethylamine (NDEA) N-Nitrosoethylisopropylamine (NEIPA) and N-Nitrosodiisopropylamine (NDIPA) Impurity Assay by GC-MS\/MSe 2019. https:\/\/www.fda.gov\/media\/124025\/download?attachment. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_97_1","unstructured":"European Directorate for the Quality of Medicines & Healthcare (EDQM). Determination of Nitrosamine Impurities in Sartan Pharmaceuticals by UHPLC-APCI-MS\/MS: CVUA Karlsruhe Method; EDQM: Strasbourg France 2021. https:\/\/www.edqm.eu\/documents\/52006\/290719\/CVUA+Karlsruhe+method+based+on+UHPLC-APCI-MS_MS.pdf. (accessed Mar. 15 2025)."},{"key":"e_1_3_5_98_1","unstructured":"European Medicines Agency (EMA). Assessment Report: Nitrosamines (EMEA\/H\/A53(1490)); Scientific Opinion; Committee for Medicinal Products for Human Use (CHMP): Amsterdam Netherlands June 20 2020. https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf. (accessed March 20 2025)."},{"key":"e_1_3_5_99_1","unstructured":"Chemisches und Veterin\u00e4runtersuchungsamt Karlsruhe. Test Method for the Determination of NDMA by LC\/MS\/MS in Valsartan Finished Products; CVUA Karlsruhe: Karlsruhe Germany 2018. https:\/\/www.cvua-karlsruhe.de\/pdfs\/omcl-method-determination-ndma-valsartan-cvua-september2018.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_100_1","unstructured":"European Medicines Agency (EMA). Lessons learnt from presence of N-nitrosamine impurities in sartan medicines 2020;1\u201398. https:\/\/www.ema.europa.eu\/en\/documents\/report\/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdf. (accessed Mar. 23 2025)."},{"key":"e_1_3_5_101_1","unstructured":"Health Canada. Nitrosamine impurities in medications: Test methods and test results. Test method for sartans or angiotensin II receptor blockers (ARBs). https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/nitrosamine-impurities\/test-results.html. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.22037\/ijpr.2021.115102.15195"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.1063"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.5478\/MSL.2021.12.2.31"},{"key":"e_1_3_5_105_1","unstructured":"Agilent Technologies. Analysis of Nitrosamines in Sartan Pharmaceuticals Using GC\/MS\/MS and LC\/MS\/MS; Application Note Publication Number 5994-1821EN; Agilent Technologies: Santa Clara CA 2019. https:\/\/www.agilent.com\/cs\/library\/applications\/application-nitrosamines-sartans-7890-8890-7010b-5994-1821en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_106_1","unstructured":"Agilent Technologies. Analysis of Pharmaceuticals Using the Agilent 6546 LC\/Q-TOF Mass Spectrometer; Application Note Publication Number 5994-1372EN; Agilent Technologies: Santa Clara CA 2020. https:\/\/www.agilent.com\/cs\/library\/applications\/application-pharmaceuticals-6546-q-tof-5994-1372en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_107_1","unstructured":"Agilent Technologies. Analysis of Nitrosamine Impurities Using the Ultivo Triple Quadrupole LC\/MS System; Application Note Publication Number 5994-1383EN; Agilent Technologies: Santa Clara CA 2020. https:\/\/www.agilent.com\/cs\/library\/applications\/application-nitrosamine-impurities-ultivo-triple-quadrupole-lc-ms-5994-1383en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_108_1","unstructured":"Agilent Technologies. Analysis Method for Nitrosamines in Sartan Pharmaceuticals Using the Agilent 8890 GC\/7010B Triple Quadrupole MS System; Application Note Publication Number 5994-4618EN; Agilent Technologies: Santa Clara CA 2021. https:\/\/www.agilent.com\/cs\/library\/applications\/application-method-nitrosamines-sartan-8890-7010b-5994-4618en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_109_1","unstructured":"Agilent Technologies. Analysis of Nitrosamine Impurities in Drug Products by GC-MS\/MS; Application Note Publication Number 5994-5795EN; Agilent Technologies: Santa Clara CA 2022. https:\/\/www.agilent.com\/cs\/library\/applications\/an-nitrosamine-impurities-drug-products-gc-ms-ms-5994-5795en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_110_1","unstructured":"Agilent Technologies. Analysis of NDMA in Ranitidine Using the 6470A Triple Quadrupole LC\/MS System; Application Note Publication Number 5994-1668EN; Agilent Technologies: Santa Clara CA 2020. https:\/\/www.agilent.com\/cs\/library\/applications\/application-ndma-ranitidine-6470a-tq-lcms-5994-1668en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_111_1","unstructured":"Agilent Technologies. Analysis of Nitrosamine and Other Mutagenic Impurities in Metformin Using the 6470 Triple Quadrupole LC\/MS System; Application Note Publication Number 5994-2286EN; Agilent Technologies: Santa Clara CA 2021. https:\/\/www.agilent.com\/cs\/library\/applications\/application-nitrosamine-mutagenic-impurities-metformin-6470-lc-ms-tq-5994-2286en-agilent.pdf. (accessed Mar. 25 2025)."},{"key":"e_1_3_5_112_1","unstructured":"Waters Corporation. High-Sensitivity Quantitation of Nitrosamine Genotoxic Impurities: LC-MS Analysis of Ranitidine Drug Product Using the Waters ACQUITY UPLC I-Class\/Xevo TQ-XS Tandem Quadrupole Mass Spectrometer; Application Note; Waters Corporation: Milford MA 2020. https:\/\/www.waters.com\/nextgen\/in\/en\/library\/application-notes\/2020\/high-sensitivity-quantitation-of-nitrosamine-genotoxic-impurities-lc-ms-analysis-of-ranitidine-drug-product-using-the-waters-acquity-uplc-i-class-xevo-tq-xs-tandem-quadrupole-mass-spectrometer.html. (accessed Apr. 2 2025)."},{"key":"e_1_3_5_113_1","unstructured":"Shimadzu Corporation. Analysis of Nitrosamine Impurities in Pharmaceuticals by LC-MS\/2S; Application Note No. IPO-219151; Shimadzu Corporation: Kyoto Japan 2018. https:\/\/www.shimadzu.com\/an\/sites\/shimadzu.com.an\/files\/pim\/pim_document_file\/applications\/application_note\/13615\/ipo219151.pdf. (accessed Apr. 2 2025)."},{"key":"e_1_3_5_114_1","unstructured":"Shimadzu Scientific Instruments. Determination of DMF and NDMA in Pharmaceuticals Using LCMS-9030 Quadrupole Time-of-Flight Mass Spectrometer; Application Note No. 23949; Shimadzu Scientific Instruments: Columbia MD 2022. https:\/\/www.ssi.shimadzu.com\/sites\/ssi.shimadzu.com\/files\/pim\/pim_document_file\/ssi\/applications\/application_note\/23949\/01%20-%202_LCMS-9030%20determination%20of%20DMF%20and%20NDMA%20ver%202.pdf. (accessed Apr. 2 2025)."},{"key":"e_1_3_5_115_1","unstructured":"Shimadzu Scientific Instruments. LCMS-8050 Analysis of Nitrosamines in Pharmaceutical Products; Application Note No. 23950; Shimadzu Scientific Instruments: Columbia MD 2022. https:\/\/www.ssi.shimadzu.com\/sites\/ssi.shimadzu.com\/files\/pim\/pim_document_file\/ssi\/applications\/application_note\/23950\/LCMS-8050-analysis-of-nitrosamines.pdf. (accessed Apr. 2 2025)."},{"key":"e_1_3_5_116_1","unstructured":"Shimadzu Corporation. Analysis of Nitrosamine Impurities in Active Pharmaceutical Ingredients Using LC-MS\/MS; Application Note No. APO-220032; Shimadzu Corporation: Kyoto Japan 2022. https:\/\/www.shimadzu.com\/an\/sites\/shimadzu.com.an\/files\/pim\/pim_document_file\/applications\/application_note\/13626\/apo220032.pdf. (accessed Apr. 2 2025)."},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48344-5"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/jaoacint\/qsab100"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.3390\/app11167590"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.18579\/jopcr\/v20i4.MS21084"},{"key":"e_1_3_5_121_1","unstructured":"Pesek J. J.; Matyska M. T.; Hiltz T. Analysis of Nitrosamines Using Unique Stationary Phase Technology. Labmate Online 2020. https:\/\/www.labmate-online.com\/article\/chromatography\/1\/microsolv-technology-corp\/analysis-of-nitrosamines-using-unique-stationary-phase-technology\/3098. (accessed Mar. 5 2025)."},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.220250"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.3390\/separations9110347"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2023.100020"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.20959\/wjpps20165-6656"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202200225"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9AN02145K"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2019.04.036"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.04.035"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.02.023"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030403"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2013.12.003"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.201600589"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.05.014"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3323"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.33176\/AACB-19-00023"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.13202849.v1"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.11387"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.4236\/ajac.2021.12601"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.22037\/ijpr.2021.115222.15258"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2022.107402"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcoa.2022.100053"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2022.120711"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.834124"},{"key":"e_1_3_5_145_1","unstructured":"Parlani P.; Choudhary S.; Bharatiya P.; Guntai U.; Ponnamaneni R. K.; Pillai M.; Baghla R.; Mandita E.; Tackett B. Sensitive and Reproducible Quantification of N-Nitroso-Propranolol in a Propranolol Drug Substance and Product; Technical Note TN-1334; Phenomenex: Torrance CA 2023. https:\/\/www.phenomenex.com\/Products\/technicalnotes\/TN1334. (accessed Apr. 2 2025)."},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27217498"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.07.022"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10337-021-04115-x"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.026"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115685"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123593"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115066"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.07.017"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.matpr.2022.11.112"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3854535"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmac059"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104908"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1039\/c5lc00283d"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bms057"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.3390\/separations7010003"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2018.02.006"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2015.02.061"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9673(75)80011-2"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c00982"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40543-020-00254-2"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00669-8"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjps.galenos.2021.17702"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115003"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2023.464323"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2024.465148"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.6040"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.04.049"},{"key":"e_1_3_5_173_1","volume-title":"Development and Validation of a RapidFire-MS\/MS Method for Screening of Nitrosamine Carcinogen Impurities N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), N-Nitrosodibutylamine (NDBA), and N-Nitroso-N-Methyl-4-Aminobutyric Acid (NMBA) in ARB Drugs; Technical Report FY19-042-DPQR-T; FDA","author":"US Food & Drug Administration (USFDA)","year":"2019","unstructured":"US Food & Drug Administration (USFDA). Development and Validation of a RapidFire-MS\/MS Method for Screening of Nitrosamine Carcinogen Impurities N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), N-Nitrosodibutylamine (NDBA), and N-Nitroso-N-Methyl-4-Aminobutyric Acid (NMBA) in ARB Drugs; Technical Report FY19-042-DPQR-T; FDA; Silver Spring: Montgomery, MD, 2019."},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.113960"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.0c02774"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2024.126752"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2020.1803790"},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2024.100034"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2025.100064"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.04.016"},{"key":"e_1_3_5_181_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573411017666211108092115"},{"key":"e_1_3_5_182_1","unstructured":"US Food & Drug Administration (USFDA). Control of Nitrosamine Impurities in Human Drugs Guidance for Industry (Revision 1). Stand Methods - Nitrosamines 2021. https:\/\/www.fda.gov\/media\/141720\/download. (accessed Mar. 12 2025)."}],"container-title":["Critical Reviews in Analytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408347.2025.2512443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10408347.2025.2512443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408347.2025.2512443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:34:00Z","timestamp":1790660040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408347.2025.2512443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":182,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/10408347.2025.2512443"],"URL":"https:\/\/doi.org\/10.1080\/10408347.2025.2512443","relation":{},"ISSN":["1040-8347","1547-6510"],"issn-type":[{"value":"1040-8347","type":"print"},{"value":"1547-6510","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}